Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0024623 (gastric cancer)
 36,219 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

The efficacy of Bestatin as adjuvant immunochemotherapy in patients with resectable gastric cancer was investigated. Ninety-six patients with similar background factors were randomized into 2 groups: a control group and an experimental group, the patients in the latter group receiving a daily oral dose of 60 mg Bestatin over a long period. All 96 patients were treated with a bolus intravenous injection of mitomycin C (MMC) plus oral administration of tegafur (FT-207, FT). The survival rate of the patients in the MMC+FT+Bestatin group was more favorable than that of the patients in the MMC+FT group, but the difference was not statistically significant. The survival rates of the MMC+FT+Bestatin group patients in the stratification of stage III+IV and positive histological serosal invasion, ps(+), were significantly superior to those of the MMC+FT group patients (Logrank test: p less than 0.05). Moreover, in patients with positive histological serosal invasion, the recurrence of peritoneal dissemination was significantly suppressed in the MMC+FT+Bestatin group.
 ...
PMID:Prospective randomized controlled study on bestatin in resectable gastric cancer. 191 68

The efficacy of Bestatin as adjuvant immunochemotherapy for patients with resectable gastric cancer was investigated. Ninety-six patients with similar background factors were randomized into two groups; a control group and an experimental group, the patients in the experimental group receiving a daily oral dose of 60 mg Bestatin over a long period. All 96 patients were treated with a bolus intravenous injection of mitomycin C (MMC) plus oral administration of tegafur (FT-207, FT). The survival rate of the patients in the MMC + FT + Bestatin group was more favorable than that of the patients in the MMC + FT group, but the difference was not statistically significant. The survival rates of the MMC + FT + Bestatin group patients in the stratification of stage III + IV and positive histological serosal invasion, ps(+), were significantly superior to those of the MMC + FT group patients (Logrank test: p less than 0.05). Moreover, in patients with positive histological serosal invasion, the recurrence of peritoneal dissemination was significantly suppressed in the MMC + FT + Bestatin group.
 ...
PMID:Prospective randomized controlled study on bestatin in resectable gastric cancer--third report. 211 15

The effectiveness of Bestatin on the prognosis of gastric cancer patients was investigated in a randomized controlled trial of postoperative adjuvant chemotherapy. One hundred and sixty-two cases of gastrectomized patients were divided into two groups; a Bestatin group (83 cases, 1/2MF'C [mitomycin C 2 mg and cytosine arabinoside 20 mg i.v. twice a week for 3 weeks, FT-207 400 mg/day i.v. for 3 weeks] followed by Bestatin 30 mg/day and FT-207 0.6 g/day p.o.) and a control group (79 cases, 1/2MF'C followed by FT-207 alone). No significant differences in background factors between the two groups were found. Bestatin was slightly effective in improving the three-year survival rates of gastric cancer patients, but this was not significant. However, survival rates in the Bestatin group in Stage II, curatively operated cases, and n (-) ps (+) cases were significantly higher than those of the control group during the same postoperative period. Bestatin prolonged the disease-free interval in curatively resected cases. Thus, efficacy of Bestatin in improving survival rates was observed in the early stages of disease, but it is suggested that combination a stronger chemotherapeutic regimen may be effective in advanced cases.
 ...
PMID:[Randomized controlled trial of postoperative adjuvant chemotherapy with bestatin for gastric cancer]. 391 53

The effectiveness of Bestatin combined with Mitomycin-C, FT-207 for treating gastric cancer was investigated in a prospective randomized controlled study. All patients had undergone gastrectomy during the period from November 1980 to July 1983. Three-year survival rates revealed no difference between groups given or not given Bestatin. The effectiveness of Bestatin was confirmed by postoperative changes revealed by liver function test, especially GOT and GPT. No side effect due to Bestatin was detected.
 ...
PMID:[Postoperative adjuvant immunochemotherapy with bestatin for stomach cancer. Randomized controlled trial: first report]. 392 87

Serum immuno-suppressive acidic protein (IAP) levels increased with the invasion of cancer in to the gastric wall, the progress of lymph nodes metastasis, and also with the increase of tumor diameter of the gastric mucosa. The immunopotentiator, Bestatin was administered for 7 days to 28 patients with gastric cancer before any other therapeutic treatment. high IAP levels (over 500 micrograms/ml) in patients with stage IV cancer were remarkably improved with this treatment.
 ...
PMID:[Effect of bestatin on immuno-suppressive acidic protein in patients with stomach cancer]. 647 36